Matthew Fowler | Authors

Articles

Cemiplimab Shows Clinical Benefit for BCC After Hedgehog Inhibitor Therapy

July 31, 2021

Cemiplimab for patients with either metastatic or locally advanced basal cell carcinoma showed antitumor activity in a phase 2 trial.

Oncology Peer Review On-The-Go: Kami Maddocks, MD, on Rechallenging With Rituximab and Second-Line Therapies for R/R DLBCL

July 30, 2021

CancerNetwork® speaks with Kami Maddocks, MD, in part 2 of a 3-part series on CD19–directed agents and other second-line agent for relapsed/refractory diffuse large B-cell lymphoma.

Lenvatinib Plus Pembrolizumab Demonstrates Antitumor Activity, Maintains Safety in Metastatic RCC

July 28, 2021

The combination of lenvatinib plus pembrolizumab showed antitumor activity and a manageable safety profile for treatment-naïve or previously treated patients with metastatic renal cell carcinoma.

Pembrolizumab Plus Cetuximab Demonstrate Promising Clinical Activity for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

July 28, 2021

Data from a phase 2 clinical trial with pembrolizumab and cetuximab yielded promising clinical activity in patients with recurrent or metastatic head and neck squamous cell carcinoma.

CancerNetwork®’s Week in Review: July 26th, 2021

July 26, 2021

Here are some of the important updates from CancerNetwork last week you might have missed in the world of oncology, featuring novel combinations for triple-negative breast cancer, genetic testing for gastrointestinal malignancies, and the FDA approval of belumosudil for chronic graft-versus-host disease.

Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Effective in Korean Population With Advanced Gastric Cancer

July 26, 2021

Recent data indicated that the combination of neoadjuvant docetaxel, oxaliplatin, and S-1 followed by surgery and adjuvant S-1 was effective and tolerable in a population of Korean patients who had locally advanced gastric cancer.

Bempegaldesleukin Plus Nivolumab Appears Safe and Effective in First-Line Metastatic Melanoma

July 26, 2021

Bempegaldesleukin plus nivolumab demonstrated positive antitumor activity while maintaining a tolerable safety profile in the PIVOT-02 trial for patients with previously untreated metastatic melanoma in the first-line setting.

Convalescent Plasma Therapy Linked to Potential Survival Benefit for Patients With Hematologic Cancers and COVID-19

July 22, 2021

Patients with hematologic malignancies and COVID-19 may experience a survival benefit after receiving convalescent plasma therapy.

Adding Sintilimab to Platinum Plus Gemcitabine Demonstrated Clinical Benefit in First-Line Squamous NSCLC

July 21, 2021

Sintilimab with gemcitabine plus platinum produced superior clinical benefit for patients with locally advanced or metastatic squamous cell non–small cell lung cancer when compared with gemcitabine plus platinum alone.

Ruxolitinib Improved Overall Response in the Treatment of Glucocorticoid-Refractory or -Dependent Chronic GVHD

July 21, 2021

Compared with a control therapy, ruxolitinib increased overall response and improved failure-free survival for patients with glucocorticoid-refractory or -dependent chronic graft-versus-host disease.